Abstract:1277 Objectives: his preliminary clinical study evaluated the safety, uptake kinetics and diagnostic potential of a glutamine analog, 18F-(2S, 4R) 4-fluoroglutamine (18F-GLN), in breast cancer patients. Methods: 17 patients (Female; age 36~69y) with biopsy-proven breast cancer were investigated with MRI and PET/CT; among which13 subjects underwent whole-body dynamic 18F-GLN PET/CT for up to 60 min after injection (295.0±67.2 MBq). Remaining 4 patients underwent static scans at 30±10 min after injection. Each patient also underwent standard 18F-FDG PET/CT at 60 min after injection for comparison analysis. The kinetics of uptake in tumors and normal breast tissues were evaluated by maximal standardized uptake values (SUV). As the Ki-67 proliferation index is presently used as the key marker of prognosis, and treatment guidelines are largely based on this index, the correlation among the Ki-67 index, 18F-GLN, 18F-FDG uptake was also investigated. Results: 18F-GLN was well tolerated in all patients without adverse events. Normal breast tissue background was low (the average SUV was 0.88±0.39), a minor uptake in normal breast was observed and reached the plateau at about 30 min after injection. Uptake of 18F-GLN in breast tumors was rapid and the SUV was highest between 1 and 10 min after injection and then a gradual washout over time (32.7 % reduction in mean tumor uptake at 60 min after injection). A three-compartment model fitted the tracer kinetics well. Axillary lymph node lesions showed rapid uptake followed by a slower washout than in tumors. It was reasonable to conlcude that an early imaging window (between 1~10 min) provided the best visual results. Breast lesions as defined by MRI and biopsy were clearly visualized by 18F-GLN (SUV=3.80±1.14; range 2.11~6.86) and 18F-FDG PET (SUV=10.49±10; range 2.7~43.03) (P<0.05). The number of lesions and axillary lymph nodes detected by 18F-GLN was consistent with 18F-FDG and all of them were confirmed to be true-positive by following biopsy. The immunohistochemical staining confirmed a negative correlation between the ratio of SUVGLN to SUVFDG (SUVG-F)and Ki67 index (r= -0.61, P < 0.05). Conclusions: 18F-GLN appeared safe for use in humans and showed significant uptake in breast cancer lesions and metastatic lymph nodes. An early imaging window seems to provide the best visual results. The ratio of SUVGLN to SUVFDG might be considered as a noninvasive Ki-67 index and might add valuable information about tumor aggressiveness and prognosis. Keywords: Positron emission tomography; Breast cancer; Glutamine transport; Ki67 proliferation index

Preclinical study of an 18F-labeled glutamine derivative for cancer imaging.

PET Imaging of 18F-(2 S,4 R)4-Fluoroglutamine Accumulation in Breast Cancer: From Xenografts to Patients

[18F]tbq-C2 As a Metabolically Stable Glutamine Derivative for Cancer Imaging

Preliminary clinical trasnationl study of 18F-(2S, 4R) 4-fluoroglutamine PET/CT imaging in 17 breast cancer patients

Evaluation of (2S,4S)-4-[18F]FEBGln as a Positron Emission Tomography Tracer for Tumor Imaging

Side Chain Optimization Remarkably Enhances the in Vivo Stability of 18F-Labeled Glutamine for Tumor Imaging.

Metabolic Imaging of Glutamine in Cancer.

Facile Radiosynthesis of 18 F-labeled Β-Glutamic Acid As a New PET Tracer for Imaging Lung Cancer

Synthesis and Preliminary Evaluation of a Novel Glutamine Derivative: (2S,4s)4-[18F]febgln.

Initial experience in synthesis of (2S,4R)‐4‐[18F]fluoroglutamine for clinical application

Initial Experience in Synthesis of (2S,4R)-4-[18 F]fluoroglutamine for Clinical Application.

Preclinical evaluation of an 18 F-trifluoroborate methionine derivative for glioma imaging

Imaging Brain Metastasis Patients with 18F-(2S,4r)-4-fluoroglutamine.

18F-Fluciclovine PET Imaging of Glutaminase Inhibition in Breast Cancer Models.

Synthesis of Optically Pure 4-Fluoro-glutamines As Potential Metabolic Imaging Agents for Tumors.

Preclinical Evaluation Of An F-18-Trifluoroborate Methionine Derivative For Glioma Imaging

(2S,4r)-4-[18f]fluoroglutamine As a PET Indicator for Bone Marrow Metabolism Dysfunctional: from Animal Experiments to Clinical Application.

Synthesis and Evaluation of Novel F-18 Labeled 4-Aminoquinazoline Derivatives: Potential Pet Imaging Agents for Tumor Detection

Kit-like 18F-labeling of RGD-19F-arytrifluroborate in high yield and at extraordinarily high specific activity with preliminary in vivo tumor imaging.

The Preparation and Execution of Exploratory Human Studies on Novel 99Mtc-Labeled Glucosamine Derivatives Containing Different Phenyl Isonitriles As Promising Tumor Imaging Agents.

Optimization of Precursor Synthesis Conditions of (2S,4S)4–[18F]FPArg and Its Application in Glioma Imaging